Capricor Therapeutics to Present at Key Investor Conferences
Event summary
- Capricor Therapeutics will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026.
- The company will also participate in the Oppenheimer CNS and Neuro-Muscular Summit on the same day.
- A webcast of the Goldman Sachs presentation will be available post-event on Capricor's website.
- Capricor's lead product candidate, Deramiocel, is in late-stage development for Duchenne muscular dystrophy (DMD).
- The company is also advancing its StealthX™ exosome platform for targeted therapeutic delivery.
The big picture
Capricor Therapeutics' participation in high-profile investor conferences underscores its focus on advancing cell and exosome-based therapeutics for rare diseases. The company's lead candidate, Deramiocel, targets Duchenne muscular dystrophy, a niche but critical market. Capricor's strategic moves come amid a competitive landscape, with ongoing litigation against Nippon Shinyaku and NS Pharma adding complexity to its commercialization plans.
What we're watching
- Clinical Progress
- How the pace of Deramiocel's late-stage development will impact Capricor's market positioning.
- Investor Sentiment
- Whether the upcoming investor conferences will boost confidence in Capricor's pipeline.
- Regulatory Pathway
- The timeline for regulatory approvals and potential commercialization of Deramiocel.
Related topics